- Home
- CRVS vs ENTA Comparison
CRVS vs ENTA Comparison
Compare CRVS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- ENTA
- Stock Information
- Founded
- CRVS 2014
- ENTA 1995
- Country
- CRVS United States
- ENTA United States
- Employees
- CRVS N/A
- ENTA N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- ENTA Health Care
- Exchange
- CRVS Nasdaq
- ENTA Nasdaq
- Market Cap
- CRVS 459.0M
- ENTA 394.0M
- IPO Year
- CRVS 2016
- ENTA 2013
- Fundamental
- Price
- CRVS $8.79
- ENTA $13.58
- Analyst Decision
- CRVS Strong Buy
- ENTA Strong Buy
- Analyst Count
- CRVS 4
- ENTA 6
- Target Price
- CRVS $13.75
- ENTA $20.33
- AVG Volume (30 Days)
- CRVS 1.0M
- ENTA 370.3K
- Earning Date
- CRVS 11-04-2025
- ENTA 11-17-2025
- Dividend Yield
- CRVS N/A
- ENTA N/A
- EPS Growth
- CRVS N/A
- ENTA N/A
- EPS
- CRVS N/A
- ENTA N/A
- Revenue
- CRVS N/A
- ENTA $65,324,000.00
- Revenue This Year
- CRVS N/A
- ENTA $2.13
- Revenue Next Year
- CRVS N/A
- ENTA $2.74
- P/E Ratio
- CRVS N/A
- ENTA N/A
- Revenue Growth
- CRVS N/A
- ENTA N/A
- 52 Week Low
- CRVS $2.54
- ENTA $4.09
- 52 Week High
- CRVS $9.55
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- CRVS 63.66
- ENTA 70.36
- Support Level
- CRVS $8.34
- ENTA $11.89
- Resistance Level
- CRVS $9.22
- ENTA $13.55
- Average True Range (ATR)
- CRVS 0.55
- ENTA 0.91
- MACD
- CRVS 0.01
- ENTA 0.16
- Stochastic Oscillator
- CRVS 83.41
- ENTA 93.41
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.